Literature DB >> 24519522

Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans.

Yu-Nan Hsu1, Calvin Q Pan, Ali Abbasi, Victor Xia, Raghav Bansal, Ke-Qin Hu.   

Abstract

BACKGROUND AND AIM: The modified normal alanine aminotransferase (ALT) value (i.e., males <30 and females <19 IU/L) is a better criteria associated with histological activity in chronic hepatitis B (CHB). This study was aimed to assess if the modified ALT criteria could be better associated with disease phases in a cohort of Asian Americans (AsAm) with CHB.
METHODS: This two-center retrospective study evaluated 198 non-treated AsAm with CHB and a mean follow-up of 21 months. Both conventional and modified ALT criteria were used to determine the differences and clinical value using modified ALT criteria in classifying CHB phases.
RESULTS: Among HBeAg (+) patients (29.3 %), HBV pre-core (PC) and basal core promoter (BCP) mutations were detected in 24.4 % and 31.3 %, respectively. Using baseline conventional ALT criteria, 97/153 (63.4 %) patients could be categorized into CHB phases 1 to 4, whereas 56/153 (36.6 %) were indeterminate. Using the modified ALT criteria, 43 (28.1 %) patients had phase changes of which 31/43 (72.1 %) were moved from phase 1 and indeterminate to phases 2 and 4, more active CHB phases. In 13/31 of these patients with liver biopsy, 6 (19.4 %) reported stage 2-4 fibrosis and 10 (32.3 %) reported grade 1-2 inflammation. Using modified ALT criteria to evaluate 48/153 patients with full data at baseline and the end of 1-year follow-up, we observed that 19/48 (39.6 %) changed their CHB phases; 5/48 (10.4 %) moved from phases 1 and 3 to phases 2 and 4; 2/48 (4.2 %) remained in the active phases; 10/48 (20.8 %) became indeterminate.
CONCLUSIONS: HBV PC and BCP mutations were detectable in 24.4 % and 31.3 % of HBeAg (+) AsAm patients, respectively. Compared with conventional ALT criteria, modified ALT criteria is more sensitive in identifying CHB patients in active phases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519522     DOI: 10.1007/s10620-014-3054-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update.

Authors:  Myron John Tong; Leeyen Hsu; Patrick W Chang; Lawrence Mitchell Blatt
Journal:  J Gastroenterol Hepatol       Date:  2011-05       Impact factor: 4.029

3.  Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.

Authors:  J H Kao; P J Chen; M Y Lai; D S Chen
Journal:  Gastroenterology       Date:  2000-03       Impact factor: 22.682

4.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

5.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Barbara Coco; Gioacchino Leandro; Piero Colombatto; Juliana Monti Gorin; Ferruccio Bonino
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

6.  Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels.

Authors:  Philip S Y Tsang; Huy Trinh; Ruel T Garcia; Jeanine T Phan; Nghiem B Ha; Huy Nguyen; Khanh Nguyen; Emmet B Keeffe; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2008-05       Impact factor: 11.382

7.  Hepatitis B virus infection.

Authors:  Yun-Fan Liaw; Chia-Ming Chu
Journal:  Lancet       Date:  2009-02-14       Impact factor: 79.321

8.  Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.

Authors:  Myron John Tong; Carlos Hsien; Leeyen Hsu; Hai-En Sun; Lawrence Mitchell Blatt
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

Review 9.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.

Authors:  Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-23       Impact factor: 11.382

10.  Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe.

Authors:  F Bonino; F Rosina; M Rizzetto; R Rizzi; E Chiaberge; R Tardanico; F Callea; G Verme
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

View more
  4 in total

1.  Determination of hepatitis B phenotype using biochemical and serological markers.

Authors:  A M Di Bisceglie; M Lombardero; J Teckman; L Roberts; H L A Janssen; S H Belle; J H Hoofnagle
Journal:  J Viral Hepat       Date:  2016-12-05       Impact factor: 3.728

2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

3.  A Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis B.

Authors:  Xianqiong Gong; Jiaen Yang; Jinmo Tang; Chong Gu; Lijian Huang; Ying Zheng; Huiqing Liang; Min Wang; Chuncheng Wu; Yue Chen; Manying Zhang; Zhijian Yu; Qianguo Mao
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

4.  Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study.

Authors:  William M Lee; Wendy C King; Harry L A Janssen; Marc G Ghany; Robert J Fontana; Michael Fried; Richard K Sterling; Jordan J Feld; Junyao Wang; Douglas B Mogul; Stewart L Cooper; Adrian M Di Bisceglie
Journal:  J Viral Hepat       Date:  2021-08-11       Impact factor: 3.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.